The company also encounters competitive risks from other organizations developing therapies for chronic kidney disease.

ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company ...

ProKidney shares are trading sharply higher Wednesday morning. The stock is gaining following a marked surge on Tuesday ...

ProKidney shares surged 500% on positive Phase 2 CKD results. Read why I remain cautious about PROK stock despite the recent ...

ProKidney’s stock was the biggest gainer and most actively traded on Tuesday following “very intriguing” news regarding the ...

ProKidney shares soar on promising Rilparencel mid-stage data for chronic kidney disease. But PROK stock remains a high-risk ...

Shares of ProKidney Corp. (NASDAQ:PROK) jumped 65% in pre-market trading Wednesday, extending the dramatic rally seen on ...

Shares of ProKidney surged more than 500% on Tuesday following upbeat results from its Phase 2 REGEN-007 study and a price ...

ProKidney (NASDAQ: PROK) experienced a surge of 515% during Tuesday's trading session and gained additional 8.58% after-hours ...

US clinical-stage biotech ProKidney reported statistically-significant and clinically-meaningful positive top-line results ...

At one point, ProKidney had been running an international phase 3 trial, dubbed PROACT 2, of rilparencel alongside the ...

Live Updates Live Coverage Updates appear automatically as they are published. Nvidia Crosses $4 Trillion Market Cap 10:50 am ...